FINWIRES · TerminalLIVE
FINWIRES

$OPTI.CN

6 stories mentioning OPTI.CNUpdated just now

Every FINWIRES story that references OPTI.CN, newest first.

Mining & Metals

Optimi Health Launches Microdose Psilocybin Products for Clinical Research

Optimi Health (OPTI.CN) on Tuesday said it completed production of two microdose psilocybin finished drug products, formulated at 1 milligram and 2 mg dosages.The products are available to authorized clinical research organizations. The 1mg and 2mg dosage formats extend Optimi's psilocybin range, which already includes the 5 mg capsule formulation currently prescribed for treatment-resistant depression in Australia."Most microdosing relies on dried mushrooms, whose psilocybin content varies widely from batch to batch. Optimi's capsules instead deliver naturally derived psilocybin at a validated, consistent dose, pairing the natural source many researchers prefer with the accurate dosage that controlled research requires," chief executive Dane Stevens said.Optimi Health shares were last seen down $0.53 to $6.36 on the Canadian Securities Exchange.Price: $6.15, Change: $-0.74, Percent Change: -10.74%

$OPTI.CN
Mining & Metals

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Optimi Health (OPTI.CN) announced Wednesday the completion of its first export of naturally derived psilocybin to the United Kingdom in support of a planned Phase 2 clinical trial.The shipment includes psilocybin biomass and finished 5mg psilocybin capsules, supplied to support a planned Phase 2 clinical trial in the United Kingdom, added the company."The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression (TRD)," said the company.Optimi plans to announce the trial partner and indication at a later date.The exported product was manufactured at Optimi's GMP facility in Princeton, British Columbia, Canada, and shipped under export authorization issued by Health Canada and import authorization from the UK Home Office, stated the company.Shares of the company were last seen down $0.05 at $6.70 on the Canadian Securities Exchange.Price: $6.70, Change: $-0.05, Percent Change: -0.74%

$OPTI.CN
Mining & Metals

Optimi Health Up 10% in U.S. Pre-Market After Securing Ibogaine Supply and Starting Its Finished Drug Product Development

U.S.-listed shares of Optimi Health (OPTI.CN, OPTH) rose 10% on Monday after it secured naturally derived ibogaine from two sources, in both hydrochloride (HCl) and freebase form.Development work on the finished drug product is expected to start this summer at the company's GMP facility in British Columbia, Canada. Two dosage sizes, 50mg and 100mg, are planned in encapsulated format, it said."We are seeing a growing number of research institutions interested in ibogaine, and there is real public funding behind it now, including the $50 million program in Texas," said Optimi Chief Executive and Co-Founder Dane Stevens. "We are excited to develop and supply this product from Canada, where we have the facility, the licensing, and the experience to make it into standardized pharmaceutical dosages."Shares of the company closed down 17% to C$6.50 on Friday on the Canadian Securities Exchange.

$OPTI.CN
Mining & Metals

Optimi Health up 2.5% as It Completes Commercial 5mg Psilocybin Production Run

Optimi Health (OPTI.CN), up 2.5% on last look, on Tuesday said it completed a production run of its 5mg psilocybin finished drug product.Optimi's 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, The company also updated the product's bottling configuration to improve ease of use for prescribers and patients in the Australian market, a statement said.Additional product from the same production run is earmarked to support upcoming clinical research in the United States and clinical trials in Europe across various indications, the company noted.Optimi Health said all stages of manufacturing were completed in-house and on-site at its facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence. The company is also authorized by Health Canada to hold up to 20 kilograms of psilocybin and approximately 2,000 kilograms of biomass on site, giving it commercial-scale supply capacity.Optimi Health shares were last seen up $0.20, to $8.10, on the Canadian Securities Exchange.Price: $8.10, Change: $+0.20, Percent Change: +2.53%

$OPTI.CN
Mining & Metals

Optimi Health Closes US$15.0 Million Public Offering of Shares

Optimi Health (OPTI.CN, OPTH), down 12.8% on last look, on Thursday said it raised US$15.0 million in the public share offering connected with its listing on the Nasdaq exchange.Optimi Health, which operates in the field of psychedelic medicine, issued 2.4 million-shares at US$6.25 each. The shares began trading on Nasdaq on May 20, under the symbol "OPTH.""This marks a significant milestone for Optimi," said chief executive Dane Steven. "This financing provides significant strength to our balance sheet and represents the necessary working capital for the growth of our business, with ample runway to scale over the next few years."Optimi Health shares were last seen down $1.05, to $7.15, on the Toronto Stock Exchange.Price: $6.95, Change: $-1.25, Percent Change: -15.24%

$OPTH$OPTI.CN
Mining & Metals

Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing

Optimi Health (OPTI.CN) plans to complete a portion of its previously announced offering of common shares in Canada pursuant to the Listed Issuer Financing Exemption contained in Part A of National Instrument 45-106 - Prospectus Exemptions, as modified by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption, said the company on Thursday.The offering price and certain terms of the securities to be offered will be determined in the context of the market at the time of pricing, said the company.A registration statement relating to these securities has been filed with the SEC but has not yet become effective, added the company.The closing of the offering is subject to market and other customary conditions, including, but not limited to, the receipt of all necessary approvals, including the approval of the Canadian Securities Exchange, the Nasdaq Capital Market and the United States Securities and Exchange Commission's review process.

$OPTI.CN

Track with the FINWIRES app suite

FolioX
FolioX
Track OPTI.CN in your portfolio
WheelAI
WheelAI
Analyze OPTI.CN options with the wheel strategy
StockInsider
StockInsider
See market sentiment on OPTI.CN